Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer-Reference-Cited by-同舟云学术

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

Published:2022-07-21 Issue:2 Volume:12 Page:1269-1278
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Udagawa Hibiki¹^ORCID,Takahashi Shunji²,Hirao Motohiro³,Tahara Makoto⁴,Iwasa Satoru⁵,Sato Yasuyoshi²,Hamakawa Takuya³,Shitara Kohei⁶^ORCID,Horinouchi Hidehito⁷^ORCID,Chin Keisho⁸,Masuda Norikazu⁹^ORCID,Suzuki Takuya¹⁰,Okumura Shiori¹⁰,Takase Takao¹¹,Nagai Reiko¹¹,Yonemori Kan¹²

Affiliation:

1. Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

2. Department of Medical Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Surgery National Hospital Organization Osaka National Hospital Osaka Japan

4. Department of Head and Neck Medical Oncology National Cancer Canter Hospital East Kashiwa Japan

5. Department of Experimental Therapeutics National Cancer Center Hospital Tokyo Japan

6. Department of Gastroenterology and Gastrointestinal Oncology National Cancer Canter Hospital East Kashiwa Japan

7. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

8. Department of Gastroenterology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

9. Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan; Current position: Department of Breast and Endocrine Surgery Nagoya University Graduate School of Medicine Nagoya Japan

10. Japan and Asia Clinical Development Department Oncology Business Group, Eisai Co., Ltd. Tokyo Japan

11. Clinical Data Science Department Medicine Development Center, Eisai Co., Ltd. Tokyo Japan

12. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4996

Reference18 articles.

1. Eisai Co Ltd.Halaven (eribulin mesylate) [package insert].2020.

2. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

3. Eisai Inc.Halaven (eribulin mesylate) [package insert]. Woodcliff Lake NJ2021.

4. Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort;Clinical Cancer Research;2024-01-31

2. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort;Cancer Research Communications;2024-01-29

3. Design of Photonic Crystal Biosensors for Cancer Cell Detection;Micromachines;2023-07-23

4. Nanodrugs systems for therapy and diagnosis of esophageal cancer;Frontiers in Bioengineering and Biotechnology;2023-07-13

5. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib;Cancer Research Communications;2023-07-10